• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Tonix Pharm Holdings (NQ: TNXP )

    0.1475 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Sep 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 148,763
    Open 0.1475
    Bid (Size) 0.1450 (1)
    Ask (Size) 0.1468 (3)
    Prev. Close 0.1475
    Today's Range 0.1475 - 0.1475
    52wk Range 0.1313 - 26.56
    Shares Outstanding 22,004,159
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Awarded Patent Covering Intranasal Delivery of FDA-Approved Tosymra to Treat Migraines
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property Product Safety
    Looking Into Tonix Pharmaceuticals's Recent Short Interest
    Via Benzinga

    Performance

    YTD
    -98.90%
    -98.90%
    1 Month
    -56.62%
    -56.62%
    3 Month
    -87.61%
    -87.61%
    6 Month
    -98.59%
    -98.59%
    1 Year
    -99.42%
    -99.42%

    More News

    Read More
    BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp.’s (NASDAQ: TNXP) TNX-801 Positioned as Viable Contender in Global Fight Against Mpox
    Via Investor Brand Network
    Exposures Product Safety
    New Hope for Mpox? How TNX-801 Could Meet the WHO's Vaccine Targets for a Safer, Single-Dose Solution
    Via ACCESSWIRE
    BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Reports TNX-801 Aligns with WHO Preferred TPP for Mpox Vaccines
    Via Investor Brand Network
    As Research Into Pain Accelerates, a Newly Recognized Type of Pain Comes to the Forefront – Tonix Targets It With FDA-Fast Track-Designated TNX-102 SL
    Via ACCESSWIRE
    BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Names Seasoned Veteran as New EVP of Commercial Operations
    Via Investor Brand Network
    Exposures Product Safety
    BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Presents Positive Preclinical Data Demonstrating TNX-801’s Single-Dose Immune Protection Against Mpox
    Via Investor Brand Network
    Exposures Product Safety
    What's Going On With Tonix Pharmaceuticals (TNXP) Stock?
    Via Benzinga
    Why Summit Therapeutics Shares Are Trading Higher By Around 18%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    InvestorNewsBreaks – Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Launches Educational Campaign to Inspire Patients to Optimize Migraine Treatment Plans with Non-Oral Medication
    Via Investor Brand Network
    Exposures Product Safety
    BioMedNewsBreaks — Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Developing Fast-Track-Designated Treatment for Fibromyalgia
    Via Investor Brand Network
    Exposures Product Safety
    Tonix Pharma Collaborates With World's Largest Vaccine Manufacturer For Mpox Vaccine
    Via Benzinga
    Tonix Pharmaceuticals and Bilthoven Biologicals to Collaborate on Advancing Development of Tonix’s Mpox Vaccine, TNX-801
    Via FinancialNewsMedia
    Modern Twist to Centuries-Old Smallpox Vaccine Poised to Combat Deadly Mpox Strain as WHO Declares Global Emergency
    Via ACCESSWIRE
    What's Going On With Tonix Pharmaceuticals (TNXP) Stock?
    Via Benzinga
    Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    TNXP Stock Earnings: Tonix Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024
    Via InvestorPlace
    Tonix Pharmaceuticals' Live Virus Vaccine Candidate Shows Long-Term Protection From Mpox, Smallpox With 1 Dose, Animal Study Suggests
    Via Benzinga
    FDA Recognizes Fibromyalgia as a 'Serious Condition' And Fast-Tracks New Drug Candidate
    Via ACCESSWIRE
    Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
    Via FinancialNewsMedia
    Exposures Product Safety
    Global Fibromyalgia Treatment Market Projected To Reach $3.86 Billion By 2031 as Positive Growth Trends Expected
    From FN Media Group LLC
    Via GlobeNewswire
    Beyond "One Bug, One Drug" - Tonix Pharmaceuticals Secures Up To $34 Million In Funding From The U.S. Department Of Defense To Develop a Broad-Spectrum Antiviral
    Via ACCESSWIRE
    Tonix Pharmaceuticals receives positive feedback from FDA on Tonmya™ for fibromyalgia management
    Via News Direct
    Exposures Product Safety
    Tonix Pharmaceuticals, Set to File an NDA for Tonmya for the Management of Fibromyalgia, is Planning Expected Launch in 2H 2025
    Via ACCESSWIRE
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.